TBPMF News and Press, Tetra Bio-Pharma Inc From 11/16/20

Plenitude Trial initiated Tetra completes clinical study assessing the metabolism profile of cannabinoids in humans Achieved development of ARDS-003 sterile injectable nano-emulsion for human use OTTAWA, ON / ACCESSWIRE / November 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" o...

Initial Drug Indication Targets COVID-19 Related Survival Benefits Cost-Saving Including When Used With a Remdesivir™ Standard of Care Expanded Post-Survival Indications (Reduce the Risk of Fibrosis and Multi-Organ Dysfunctions) Tetra Estimates Potential Revenues From ...

Tetra Bio-Pharma Inc. Acquires Common Shares of Mondias Natural Products Inc. Canada NewsWire OTTAWA, ON, Nov. 2, 2020 OTTAWA, ON , Nov. 2, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. (" Tetra " or the "Company" ) (TSX: TBP) (OTCQB: TBPMF) is please...

OTTAWA, ON / ACCESSWIRE / October 28, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:TBP )( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, today announces that it has completed the divestiture of Lumiera Health Innovation Inc. ("Lumiera"), its...

Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID OTTAWA...

IntelGenx ([[IGXT]] +4.9%) has entered into an amended and restated license agreement granting Tetra Bio-Pharma ([[TBPMF]] +5.6%) additional worldwide exclusive rights for the mucoadhesive delivery technology for its PPP-002 (Dronabinol) drug candidate.In addition to the Dronabinol ...

SAINT LAURENT, Quebec, Oct. 21, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into an amended and restated license agreement (the “Agreement”) granting Tetra Bio-Pharma (TSX:TBP)(OTCQB:T...

Tetra will leverage its recent Dronabinol data pack acquisition to rapidly file its second New Drug Submission application to commercialize another THC-based prescription drug Further reinforces its patent protection and life cycle management on its dronabinol franchise Shown in a...

Reduced the levels of key inflammatory cytokine markers Reduced fibrosis when the lung tissue was analyzed Reduced the effects of fibrosis-associated inflammatory pathways OTTAWA, ON / ACCESSWIRE / October 20, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:T...

DIN submission to be completed in Q4 2020 OTTAWA, ON / ACCESSWIRE / October 7, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:TBP ) ( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, is pleased to provide an update on its commercial strat...